BioXcel Therapeutics (BTAI) Non Operating Interest Expenses (2019 - 2026)

BioXcel Therapeutics has reported Non Operating Interest Expenses for 8 years, with the latest figure at $4.3 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 0.83% year-over-year to $4.3 million in Q2 2026; TTM through Jun 2026 was $17.2 million, a 7.4% increase from a year earlier, with the FY2025 full-year figure at $17.0 million, up 12.26% from the prior year.
• Non Operating Interest Expenses was $4.3 million for Q2 2026 at BioXcel Therapeutics, up from $4.2 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $4.4 million in Q4 2025, with the low at $7000.0 in Q1 2022.
• Average Non Operating Interest Expenses over 5 years is $3.4 million, with a median of $3.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Non Operating Interest Expenses soared 48566.67% in 2022, then fell 12.11% in 2023.
• Over 5 years, Non Operating Interest Expenses stood at $2.9 million in 2022, then climbed by 17.64% to $3.4 million in 2023, then advanced by 17.38% to $4.0 million in 2024, then increased by 9.03% to $4.4 million in 2025, then declined by 3.16% to $4.3 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $4.3 million (Q2 2026), $4.2 million (Q1 2026), and $4.4 million (Q4 2025), per Business Quant data.